REPO-STROKE II, a Phase IIa clinical study in patients with acute ischemic stroke, has enrolled its first patient. The trial investigates a triple combination of three drugs approved for other therapeutic uses on top of standard therapy. In this context the consortium published a press release with the topic ‘REPO-STROKE II, THE THREE-COMPONENT DRUG REPURPOSING STUDY, STARTS INCLUSION OF PATIENTS‘. Read more.
